Globus Medical (GMED) Expected to Release Quarterly Earnings on Thursday

Globus Medical (NYSE:GMED) is expected to post its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to announce earnings of $1.10 per share and revenue of $782.8540 million for the quarter. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Investors can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:30 PM ET.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The business had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. Globus Medical’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.68 earnings per share. On average, analysts expect Globus Medical to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Globus Medical Trading Up 3.4%

NYSE GMED opened at $81.44 on Tuesday. Globus Medical has a 1 year low of $52.56 and a 1 year high of $101.40. The company has a fifty day simple moving average of $79.47 and a 200 day simple moving average of $85.51. The company has a market cap of $11.05 billion, a P/E ratio of 18.94, a P/E/G ratio of 1.63 and a beta of 0.95.

Analysts Set New Price Targets

GMED has been the subject of a number of research analyst reports. Truist Financial cut their target price on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Thursday, July 16th. Wells Fargo & Company lowered their price target on Globus Medical from $104.00 to $103.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Zacks Research lowered Globus Medical from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. BMO Capital Markets assumed coverage on Globus Medical in a research report on Wednesday, July 8th. They set an “outperform” rating and a $94.00 price objective for the company. Finally, Stifel Nicolaus cut their price objective on Globus Medical from $95.00 to $80.00 and set a “hold” rating for the company in a research report on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $102.08.

Insider Buying and Selling

In other Globus Medical news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $80.76, for a total value of $2,019,000.00. Following the completion of the sale, the director owned 510,175 shares in the company, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 18.38% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of GMED. AQR Capital Management LLC increased its holdings in Globus Medical by 45.9% in the 1st quarter. AQR Capital Management LLC now owns 22,510 shares of the medical device company’s stock valued at $1,622,000 after buying an additional 7,086 shares during the period. Integrated Wealth Concepts LLC lifted its holdings in shares of Globus Medical by 33.0% during the 1st quarter. Integrated Wealth Concepts LLC now owns 4,375 shares of the medical device company’s stock worth $320,000 after acquiring an additional 1,085 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Globus Medical by 38.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,649 shares of the medical device company’s stock worth $2,228,000 after acquiring an additional 8,540 shares during the period. Jones Financial Companies Lllp boosted its position in shares of Globus Medical by 237.3% during the 1st quarter. Jones Financial Companies Lllp now owns 850 shares of the medical device company’s stock valued at $62,000 after acquiring an additional 598 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Globus Medical by 8.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 347,527 shares of the medical device company’s stock valued at $25,439,000 after acquiring an additional 28,027 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.